Stability of CSF β-amyloid1-42 and tau levels by APOE genotype in Alzheimer patients

Dementia and Geriatric Cognitive Disorders

Volumn 22, Issue 1, 2006, Pages 48-53

  Huey, Edward D ^a,c   Mirza, Nadeem ^a   Putnam, Karen T ^a   Soares, Holly ^b   Csako, Gyorgy ^a   Levy, James A ^a   Copenhaver, Brittany ^a   Cohen, Robert M ^a   Sunderland, Trey ^a  

^a NATIONAL INSTITUTE OF MENTAL HEALTH   (United States)

^b PFIZER INC   (United States)

^c NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE   (United States)

Author keywords

Amyloid; Alzheimer disease diagnostic tests; APOE genotype; Cerebrospinal fluid biomarker; Tau

Indexed keywords

AMYLOID BETA PROTEIN[1-42]; APOLIPOPROTEIN E; TAU PROTEIN;

ADULT; AGED; ALLELE; ALZHEIMER DISEASE; ARTICLE; CEREBROSPINAL FLUID; CONTROLLED STUDY; GENETIC STABILITY; GENOTYPE; HUMAN; PRIORITY JOURNAL; PROTEIN STABILITY;

AGED; ALLELES; ALZHEIMER DISEASE; AMYLOID BETA-PROTEIN; APOLIPOPROTEINS E; BIOLOGICAL MARKERS; FEMALE; GENOTYPE; HUMANS; MALE; MIDDLE AGED; NEUROPSYCHOLOGICAL TESTS; PEPTIDE FRAGMENTS; TAU PROTEINS;

EID: 33745225239     PISSN: 14208008     EISSN: None     Source Type: Journal    
DOI: 10.1159/000093261     Document Type: Article

References (24)

1. Hampel H, Mitchell A, Blennow K, Frank RA, Brettschneider S, Weller L, Moller HJ: Core biological marker candidates of Alzheimer's disease - perspectives for diagnosis, prediction of outcome and reflection of biological activity. J Neural Transm 2004;111:247-272.
2. Sunderland T, Linker G, Mirza N, Putnam KT, Friedman DL, Kimmel LH, Bergeson J, Manetti GJ, Zimmermann M, Tang B, Bartko JJ, Cohen RM: Decreased beta-amyloid 1-42 and increased tau levels in cerebrospinal fluid of patients with Alzheimer disease. JAMA 2003;289:2094-2103.
3. Andreasen N, Hesse C, Davidsson P, Minthon L, Wallin A, Winblad B, Vanderstichele H, Vanmechelen E, Blennow K: Cerebrospinal fluid beta-amyloid(1-42) in Alzheimer disease: differences between early- and late-onset Alzheimer disease and stability during the course of disease. Arch Neurol 1999;56:673-680.
4. Andreasen N, Vanmechelen E, Van de Voorde A, Davidsson P, Hesse C, Tarvonen S, Raiha I, Sourander L, Winblad B, Blennow K: Cerebrospinal fluid tau protein as a biochemical marker for Alzheimer's disease: a community-based follow-up study. J Neurol Neurosurg Psychiatry 1998;64:298-305.
5. Blomberg M, Jensen M, Basun H, Lannfelt L, Wahlund LO: Increasing cerebrospinal fluid tau levels in a subgroup of Alzheimer patients with apolipoprotein E allele epsilon 4 during 14 months' follow-up. Neurosci Lett 1996;214:163-166.
6. Kanai M, Matsubara E, Isoe K, Urakami K, Nakashima K, Arai H, Sasaki H, Abe K, Iwatsubo T, Kosaka T, Watanabe M, Tomidokoro Y, Shizuka M, Mizushima K, Nakamura T, Igeta Y, Ikeda Y, Amari M, Kawarabayashi T, Ishiguro K, Harigaya Y, Wakabayashi K, Okamoto K, Hirai S, Shoji M: Longitudinal study of cerebrospinal fluid levels of tau, A beta1-40, and A beta1-42(43) in Alzheimer's disease: a study in Japan. Ann Neurol 1998;44:17-26.
7. Kanai M, Shizuka M, Urakami K, Matsubara E, Harigaya Y, Okamoto K, Shoji M: Apolipoprotein E4 accelerates dementia and increases cerebrospinal fluid tau levels in Alzheimer's disease. Neurosci Lett 1999;267:65-68.
8. Tapiola T, Pirttila T, Mikkonen M, Mehta PD, Alafuzoff I, Koivisto K, Soininen H: Three-year follow-up of cerebrospinal fluid tau, beta-amyloid 42 and 40 concentrations in Alzheimer's disease. Neurosci Lett 2000;280:119-122.
9. Sunderland T, Wolozin B, Galasko D, Levy J, Dukoff R, Bahro M, Lasser R, Motter R, Lehtimaki T, Seubert P: Longitudinal stability of CSF tau levels in Alzheimer patients. Biol Psychiatry 1999;46:750-755.
10. American Psychiatric Association: Diagnostic and Statistical Manual of Mental Disorders, ed 4. Washington, American Psychiatric Association, 1994.
11. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM: Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 1984;34:939-944.
12. Dukoff R, Sunderland T: Durable power of attorney and informed consent with Alzheimer's disease patients: a clinical study. Am J Psychiatry 1997;154:1070-1075.
13. Sunderland T, Dukoff R: Informed consent with cognitively impaired patients: an NIMH perspective on the durable power of attorney. Account Res 1996;4:217-226.
14. Hughes CP, Berg L, Danziger WL, Coben LA, Martin RL: A new clinical scale for the staging of dementia. Br J Psychiatry 1982;140:566-572.
15. Reisberg B, Ferris SH, de Leon MJ, Crook T: The Global Deterioration Scale for assessment of primary degenerative dementia. Am J Psychiatry 1982;139:1136-1139.
16. Folstein MF, Robins LN, Helzer JE: The Mini-Mental State Examination. Arch Gen Psychiatry 1983;40:812.
17. Blennow K, Vanmechelen E, Hampel H: CSF total tau, Abeta42 and phosphorylated tau protein as biomarkers for Alzheimer's disease. Mol Neurobiol 2001;24:87-97.
18. Sunderland T, Mirza N, Putnam KT, Linker G, Bhupali D, Durham R, Soares H, Kimmel L, Friedman D, Bergeson J, Csako G, Levy JA, Bartko JJ, Cohen RM: Cerebrospinal fluid beta-amyloid(1-42) and tau in control subjects at risk for Alzheimer's disease: the effect of APOE epsilon4 allele. Biol Psychiatry 2004;56:670-676.
19. Nitsch RM, Rebeck GW, Deng M, Richardson UI, Tennis M, Schenk DB, Vigo-Pelfrey C, Lieberburg I, Wurtman RJ, Hyman BT, et al: Cerebrospinal fluid levels of amyloid beta-protein in Alzheimer's disease: inverse correlation with severity of dementia and effect of apolipoprotein E genotype. Ann Neurol 1995;37:512-518.
20. Tapiola T, Pirttila T, Mehta PD, Alafuzofff I, Lehtovirta M, Soininen H: Relationship between apoE genotype and CSF beta-amyloid (1-42) and tau in patients with probable and definite Alzheimer's disease. Neurobiol Aging 2000;21:735-740.
21. Arai H, Higuchi S, Sasaki H: Apolipoprotein E genotyping and cerebrospinal fluid tau protein: implications for the clinical diagnosis of Alzheimer's disease. Gerontology 1997;43:2-10.
22. Galasko D, Clark C, Chang L, Miller B, Green RC, Motter R, Seubert P: Assessment of CSF levels of tau protein in mildly demented patients with Alzheimer's disease. Neurology 1997;48:632-635.
23. Hock C, Golombowski S, Naser W, Muller-Spahn F: Increased levels of tau protein in cerebrospinal fluid of patients with Alzheimer's disease - correlation with degree of cognitive impairment. Ann Neurol 1995;37:414-415.
24. Golombowski S, Muller-Spahn F, Romig H, Mendla K, Hock C: Dependence of cerebrospinal fluid tau protein levels on apolipoprotein E4 allele frequency in patients with Alzheimer's disease. Neurosci Lett 1997;225:213-215.